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The support vector machine (SVM) and partial
least square (PLS) methods were used to develop
quantitative structure activity relationship (QSAR)
models to predict the inhibitory activity of non-
peptide HIV-1 protease inhibitors. Genetic algo-
rithm (GA) was employed to select variables that
lead to the best-fitted models. A comparison
between the obtained results using SVM with
those of PLS revealed that the SVM model is much
better than that of PLS. The root mean square
errors of the training set and the test set for SVM
model were calculated to be 0.2027, 0.2751, and
the coefficients of determination (R2) are 0.9800,
0.9355 respectively. Furthermore, the obtained
statistical parameter of leave-one-out cross-valida-
tion test (Q2) on SVM model was 0.9672, which
proves the reliability of this model. The results
suggest that TE2, Ui, GATS5e, Mor13e, ATS7m,
Ss, Mor27e, and RDF035e are the main indepen-
dent factors contributing to the inhibitory activi-
ties of the studied compounds.
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Human immunodeficiency virus (HIV), the causative agent of AIDS,
now infects millions of people worldwide. Although a cure has not
been found yet for this fatal disease, rapid advances in molecular
biology along with the 3-D elucidation of HIV proteins have led to
new drug-targeting approaches for designing antiviral agents that
specifically bind to key regulatory proteins that are essential for
HIV replication. Thus, by developing new inhibitors of HIV-1 prote-
ase activity, the treatment of AIDS can be advanced (1–6).
Peptidic and peptidomimetic non-hydrolyzable transition state mim-
ics were rapidly developed as highly potent HIV protease inhibitors
(7,8). These competitive inhibitors possess optimal interactions in
substrate binding pockets with low to subnanomolar Ki values.
However, their peptidic nature often makes them poor pharmaco-
logical agents, with low bioavailability and rapid clearance (8). Sev-
eral peptidic inhibitors are currently under clinical trials and
significant efforts to improve their pharmacology continues. In this
study, we picked out small non-peptide HIV protease inhibitors with
potentially better pharmacological characteristics based on the
structural features of peptidic inhibitors bound to the enzyme (9),
and performed quantitative structure activity relationship (QSAR)
studies.
QSAR studies resort to several statistical techniques, which can
be applied for model construction. For example, multiple linear
regressions (MLR) and artificial neural networks (ANN) (10–16)
are used for inspection of linear and non-linear correlations
between activity and molecular descriptors respectively. Neural
networks have some problems inherent to their architecture, such
as overtraining, overfitting, network optimization, and reproducibil-
ity of results. This is mainly because of random initialization of
the networks and variation of stopping criteria (17). Because of
these limitations, other more accurate and informative QSAR
techniques are used. The support vector machine (SVM) is a
new algorithm developed from the machine learning community
(18). SVM approach automatically controls the flexibility of the
resulting classifier on the training data. Accordingly, by the
design of the algorithm, the deteriorating effect of the input
dimensionality on the generalization ability is largely suppressed.
Owing to its remarkable generalization performance, the SVM
has attracted attention and gained extensive application, such as
pattern recognition problems (17,19), drug design (20), QSAR
(21,22), and quantitative structure–property relationship (QSPR)
analysis (23). In most of these cases, results obtained from SVM
modeling either matches or is significantly better than that of
traditional machine learning approaches. The work presented here
employs SVM in predicting inhibitory activity of non-peptidic HIV-
1 protease inhibitors.
In this research, we performed QSAR study on the inhibitory activity
of non-peptide HIV-1 protease inhibitors using the SVM technique.
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Performance of this model was compared with that of the PLS
method.
Materials and methods
Data set
The data used in this QSAR study consisted of inhibitory activity
data (IC50), which is the half maximal (50%) inhibitory concentration
(IC) of a compound, have been reported by Tummino et al. (24). The
activity data [IC50 (lM)] for non-peptide HIV-1 protease inhibitors
(Table 1) was converted to the logarithmic scale [)log IC50 (M)]
and then used for subsequent QSAR analyses as the response vari-
ables. Figure 1 shows the general structure of non-peptide HIV-1
protease inhibitors.
Software
Geometry optimization was performed using HyperChema (Version
7.5 Hypercube, Inc., Gainesville, FL, USA). Dragonb 5.0 (Milano
Chemometrics and QSAR Research Group, Milano, Italy) software
was utilized to calculate the molecular descriptors. The SPSS
software (version 16.0, SPSS, Inc., IL, USA) was employed for the
simple statistical analysis. The SVM evaluations were carried out
using the SVM toolbox for use with Matlab (Version 7.6, Math
works, Inc., Natick, MA, USA) that was developed by Gunn (25).
Descriptors calculation and selection
Molecular chemical structure was built using Hyperchem 7.5 soft-
ware. AM1 method (26) was applied to optimize the molecular
structure of the compounds. No molecular symmetry constraint was
applied; rather full optimization of all bond lengths and angles was
carried out. All calculations were carried out at the restricted Har-
tree-Fock level with no configuration interaction. The molecular
structures were optimized using the Polak–Ribiere algorithm until
the root mean square gradient was 0.01 Kcal ⁄mol.
Geometry optimization was run multiple times with different start-
ing points for each molecule, and the lowest energy conformation
was considered for the calculation of electronic properties. The
resulting geometry was transferred into the Dragon program pack-
age developed by Milano Chemometrics and QSPR Group to calcu-
late descriptors in Constitutional, Topological, Geometrical, Charge,
GETAWAY (GEometry, Topology and Atoms-Weighted AssemblY),
WHIM (Weighted Holistic Invariant Molecular descriptors), 3D-
MoRSE (3D Molecular Representation of Structure based on Elec-
tron diffraction), Molecular Walk Count, BCUT, 2D-Autocorrelation,
Aromaticity Index, Randic molecular profile, Radial Distribution
Function, Functional group, and Atom-Centered Fragment classes.
Molecular descriptors (1481) belonging to eighteen different theo-
retical descriptors were calculated for each molecule. The calcu-
lated descriptors were first analyzed for the existence of constant
or near constant variables. The detected ones were then removed.
Correlation among descriptors with the activity of the molecules
was examined and collinear descriptors (i.e. r > 0.9) were
detected. Descriptors that contain a high percentage (> 90%) of
identical values were discarded to decrease the redundancy exist-
ing in the descriptor data matrix. Among the collinear descriptors,
the one presenting the highest correlation with the activity was
retained and others were removed from the data matrix. The
dataset was splitted into two sets based on activity range; train-
ing set (85%) with activity ranges from 3.921 to 8.444 and test
set (15%) with activity ranges from 4.538 to 8.208 (27). In this
work, genetic algorithm (GA) variable subset selection method (28)
was used for the selection of the most relevant descriptors from
the pool of remaining descriptors. These descriptors would be
Table 1: Activity data [pIC50 (M)] for non-peptide HIV-1 protease
inhibitorsa
No. R1 R2 R3 Chirality n pIC50
1 – – – – 5.161
2 – – – – 5.091
3 – – – – 4.721
4 – – – – 4.538
5b – – – – 4.538
6 H H (CH2)3OPh 5.638
7 H H CH2Ph 3.921
8 H H CH(Ph)CH2COCH3 4.745
9 CH3 CH3 CH(Ph)CH2COCH3 5.721
10 H H (CH2)3SPh 4.585
11 H H (CH2)4Ph 3.959
12 H H (CH2)4-Ph(2-OCH3) 5.769
13 OH H (CH2)4-Ph(2-OCH3) 6.284
14 H Ph 5.523
15 H CH2Ph 5.769
16 H CH2CH2Ph 5.886
17 4-OH CH2CH2Ph 6.284
18b 4-OCH2CO2H CH2CH2Ph 6.796
19 H Ph(2-Me) 6.377
20 H Ph(2-iPr) 7.432
21 H Ph(2-tBu) 7.769
22 (3-Me) Ph(2-iPr) 8.155
23 Ph Ph 6.108
24b Isobutyl Ph 6.387
25 Ph CH2Ph 6.319
26 Isobutyl CH2Ph 6.585
27 CH2-cyclopropyl CH2Ph 7.076
28 CH2-cyclopropyl Cyclohexyl 6.824
29 CH2-cyclopropyl Cyclopentyl 7.161
30b Isobutyl Cyclopentyl 7.236
31 Cyclopentyl Cyclopentyl 6.638
32 H 2 5.677
33 CH3(CH2)2 2 5.292
34 CH3(CH2)4 2 7.076
35b (CH3)2CH(CH2)2 2 7.018
36 HO2C(CH2)4 2 8.301
37 Ph 1 6.585
38 Ph(CH2)2 1 7.222
39 H H 6-R,S 6.886
40b Me H 6-R,S 7.137
41 Isopropyl H 6-R,S 7.854
42 Isopropyl Me 6-R,S 8.137
43 Isopropyl Me 6-R 6.886
44b Isopropyl Me 6-S 8.208
45 t-Butyl H 6-R,S 8.444
46 t-Butyl Me 6-R,S 8.009
aSee Figure 1 for the general structure of the compounds under study.
bCompounds in the test set.
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used as inputs of PLS and SVM for the construction of QSAR
models.
Genetic algorithm
Genetic algorithms are an interesting and widely used variable
selection method. It applies Darwin evolution hypothesis and differ-
ent genetic functions, i.e. crossover and mutation to optimize prob-
lems defined by fitness criteria.
To select the most relevant descriptors, population evolution was
simulated (29–31) using the first generation population selected
randomly. Each individual member in the population, defined by a
chromosome of binary values, represents a subset of descriptors.
The number of the genes at each chromosome was equal to the
number of the descriptors. A gene was given the value of 1, if its
corresponding descriptor was included in the subset; otherwise, it
was given zero value. The number of genes with the value of 1
was kept relatively low to have a small subset of descriptors (32).
As a result, the probability of generating 0 for a gene was greater
(at least 60%) than the probability of generating 1. The operators
used here were crossover and mutation. The application probability
of these operators varied linearly with a generation renewal (0–
0.1% for mutation and 60–90% for crossover). The population size
varied between 50 and 250 for different GA runs. For a typical run,
the evolution of the population stopped when 90% of the members
displayed the same fitness.
Partial least square (PLS)
PLS is the method used for building regression models on the latent
variable decomposition relating two blocks, matrices X and Y,
which contain the independent x and dependent y variables respec-
tively. These matrices can be simultaneously decomposed into a
sum of f latent variables, as follows:
X ¼ TP T þ E ¼
X
t f p 00f þ E ð1Þ
Y ¼ UQT þ F ¼
X
uf q0f þ F ð2Þ
in which T and U are the score matrices for X and Y respectively.
Pand Q are the loadings matrices for X and Yrespectively. E and F
Figure 1: General structure of
non-peptide HIV-1 protease inhib-
tor.
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are the residual matrices. The two matrices are correlated by the
scores T and U, for each latent variable, as follows:
uf ¼ bf tf ð3Þ
where bf is the regression coefficient for thef latent variable. The
matrix Y can be calculated from uf, as shown in eqn 4, and the
acidity constant of the new samples can be estimated from the
new scores T*, which are substituted in eqn 4, leading to eqn 5
Y ¼ TBQ T þ F ð4Þ
Ynew ¼ T BQT ð5Þ
In this procedure, it is necessary to find the best number of latent
variables, which is normally performed using cross-validation that is
based on the determination of minimum prediction error. Applica-
tions of PLS have been discussed by several researchers (10,33).
Support vector machine
SVM can be applied to regression by the introduction of an alterna-
tive loss function and the results appear to be very encouraging. In
support vector regression (SVR), the basic idea is to map the data
X into a higher-dimensional feature space F via a non-linear map-
ping F and then to do linear regression in this space. Therefore,
regression approximation addresses the problem of estimating a
function based on a given data set G ¼ ðxi ; yiÞf gNi¼1 (xi contains
independent variables, yi contains dependent variables, and N is
the total number of data patterns). SVM approximates the function
in the following form:
f ðxÞ ¼
XN
i¼1
wiUðxÞ þ b ð6Þ
where w is weight vector, ðUiðxÞf gNi¼1 is the set of mappings of
input features, wif gNi¼1 and b are the slope and offset of the
regression function respectively. They are estimated by minimizing
the following cost function;
RðC Þ ¼ 1
2
wk k2þ C
N
XN
i¼1
Leðyi  f ðxiÞ; eÞ ð7Þ
Where
Leðyi  f ðxiÞ; eÞ ¼ 0 if jyi  f ðxiÞj  ejyi  f ðxiÞj  e otherwise
 
ð8Þ
e is a precision parameter representing the radius of the tube
located around the regression function f(x).
In eqn 7, [ wk k2] is the regularization term that controls the trade-
off between the complexity and the approximation accuracy of the
regression model to ensure that the model possesses an improved
generalized performance. The second term
[C=N
PN
i Leðyi  f ðxiÞ; eÞ] is the so-called empirical error (risk)
measured by e-insensitive loss function Le (yi - f(xi)), which indicates
that it does not penalize errors below e ‡ 0. C is the regularized
constant determining the trade-off between the empirical risk and
regularization term. Introduction of slack variables 'n' leads eqn 7
to the following constrained function: Min.
Rðw ; n; nÞ ¼ 1
2
wk k2þC
XN
i¼1
ðni þ ni Þ ð9Þ
Subjected to
wUðxiÞ þ b  yi  eþ ni ;
yi  wUðxiÞ  bi  eþ ni e; ni ; ni  0 ð10Þ
By using Lagrangian multipliers and Karush–Kuhn–Tucker conditions
to the eqn 9, it yields the following dual Lagrangian form (34),
Maximize:
PSIðai ; ai Þ ¼ 
1
2
XN
i¼1
XN
i¼1
ðai  ai Þðaj  aj ÞK ðxi ; xj Þ
 e
XN
i¼1
ðai þ ai Þ þ
XN
i¼1
ðai  ai Þyi
ð11Þ
with the following constrains
XN
i¼1
ðai  ai Þ ¼ 0; 0  ai  C and 0  ai  C ð12Þ
The Lagrangian multipliers in eqn 11 satisfy the equality
ai  ai ¼ 0 (35,36). The Lagrangian multipliers ai and ai are cal-
culated, and an optimal desired weight vector of the regression hy-
perplan is w ¼ PN
i¼1
ðai  ai ÞK ðxi ; xjÞ. Hence, the general form
of the SVR-based regression function can be written as (34,37):
f ðx ;wÞ ¼ f ðx ; ai ; ai Þ ¼
XN
i¼1
ðai  ai ÞK ðxi ; xj Þ þ b ð13Þ
Based on the Karush–Kuhn–Tucker (KKT) conditions (38,39) of qua-
dratic programming, only a number of coefficients ai and ai will
be non-zero, and the data points associated with these parameters
refer to the support vectors of the model.
In eqn 13, K(xi,xj) is the kernel function. The value is equal to the
inner product of two vectors xi and xj in the feature space F(x).
That is K(xi,xj) = F(xi)F(xj). The elegance of using kernel function
stems from the fact that one can deal with feature spaces of arbi-
trary dimensionality without having to compute the map F(x) explic-
itly. Any function that satisfies Mercer's condition can be used as
the kernel function.
In this work, the Gaussian radial basis function (RBF) kernel was
used as kernel function, k(xi,xj) = exp ()(||x
i )xj||
2) ⁄ 2r2), where r2
is the width of the Gaussian function, so the C and r that are the
relative weights of the regression error and the kernel parameter
of the RBF kernel should be optimized by the user, to obtain the
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support vector. The parameters of SVMR were optimized by system-
ically changing their values in the training step and calculating the
RMSE and accuracy of the model using 5-fold cross-validation. The
optimized values of C, r2, and e were 8, 0.5, and 0.06 respectively
obtained based on minimum RMSE and maximum accuracy of
model.
Results and discussion
The prediction ability of QSAR ⁄QSPR models is affected by two
parameters: the first one is whether the descriptors carry enough
structural information to enable the interpretation of the activ-
ity ⁄ property being investigated. The second is the accuracy of the
modeling methods employed. For the selection of the most impor-
tant descriptors, genetic algorithm variable subset selection method
was used. As a rule of thumb, at least five compounds should be
included in the equation for every descriptor (40,41). The entire GA
process can be summarized as follows: (i) generate random vari-
ables subsets; (ii) evaluate each individual subset of selected de-
scriptors for fitness to predict pIC50; (iii) discard worse half of
individuals; (iv) breed remaining individuals (or chromosome); (v)
allow for mutation; (vi) repeat steps 2–5 until ending criteria are
met. The GA finishes when one of two conditions is found: (i) after
a finite number of iterations or (ii) after some percentage of the
individuals in the population are using identical variable subsets. It
is worth mentioning that individuals with noisy variables tend to be
discarded and, thus, the variables used by those individuals become
less represented in the overall gene population. On the other hand,
less noisy variables become more and more represented. Depending
on the number of variables and the rate of mutation, many of the
individuals eventually contain the same genes. The GA applied to
the variable selection in this article uses a binary representation as
the coding technique for the given problem; the presence or
absence of a descriptor in a chromosome is coded by 1 or 0. The
GA performs its optimization by variation and selection via the eval-
uation of the fitness function (RMSECV). The GA parameters that
were used in this study are: population size 64, maximum genera-
tions 100, mutation rate 0.005, iteration 100, and cross-over 0.6.
Eight descriptors were selected by GA, which are: TE2, Ui, GATS5e,
Mor13e, ATS7m, Ss, Mor27e, and RDF035e. Table 2 shows the
short description of these descriptors. The correlation matrix of
these descriptors is shown in Table S1 in the supplementary mate-
rial, which shows that the selected descriptors are independent. To
demonstrate the absence of chance correlations on the eight de-
scriptors obtained with the previous procedure, we performed a Y-
scrambling test on the training set, where the output values of the
compounds were shuffled randomly, and the scrambled data set
was re-examined by the PLS method against real (unscrambled)
input descriptors to determine the correlation and predictivity of the
resulting model. The R2 values obtained from the Y-randomization
test are in the range between 0.12 and 0.25. Such low values pro-
vide evidence for the absence of any chance of correlation in
observed model.
As it was mentioned previously, we employed GA method to find
the important descriptors and then we performed PLS and SVM for
a linear and non-linear modeling of the dataset, respectively.
Table S2 in the supplementary material shows that both methods
were achieved for modeling Non-peptide HIV-1 protease inhibitors.
We also obtained percent recovery of compounds to show which
model was better in predicting the pIC50.
Results of GA-PLS
Model validation was achieved through leave-one-out cross-valida-
tion (LOO CV) and external validation (for a test set), and the pre-
dictive ability was statistically evaluated through the root mean
square errors of calibration (RMSEC) and validation (RMSECV). A
leave-one-out cross-validation was carried out using the NIPALS
algorithm to find the best number of latent variables (Lv) to be
used in calibration and prediction. The calibration and prediction
qualities were quantified with R2 (training set) and Q2 (leave-one-
out cross-validation on training set). The Lv's were chosen accord-
ing to their Q2 or the prediction error sum of squares (PRESS) val-
ues for cross-validated models. Prediction error sum of squares
(PRESS) is a standard index to measure the accuracy of a model-
ing method based on the cross-validation technique. Based on the
PRESS and SSY (sum of squares of deviations of the experimental
values from their mean) statistics, the Q2 can be easily calculated
by eqn 14:
Table 2: Description of the
selected descriptors in this studyNo Symbol Class Meaning
1 TE2 Charge descriptors Topographic electronic descriptor(bond
resctricted)
2 Ui Empirical descriptors Unsaturation index
3 GATS5e 2D autocorrelations Geary autocorrelation-lag5 ⁄weighted
by atomic Sanderson electronegativities
4 Mor13m 3D-MoRSE descriptors 3D MoRSE-signal13 ⁄weighted by atomic
masses
5 ATS7m 2D autocorrelations Broto-Moreau autocorrelation of a
topological structure- lag7 ⁄ weighted by
atomic masses
6 Ss Constitutional descriptors Sum of Kier-Hall electrotopological States
7 Mor27e 3D-MoRSE descriptors 3D MoRSE-signal27 ⁄ weighted by atomic
Sanderson electronegativities
8 RDF035e RDF descriptors Radial distribution function-3.5 ⁄ weighted
by atomic Sanderson electronegativities
Deeb and Goodarzi
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Q 2LOO ¼
PRESS
SSY
¼ 1
Pn
i¼1
ðyexp  ypred Þ2
Pn
i¼1
ðyexp  yÞ2
ð14Þ
The cross-validation method employed was to eliminate only one
sample at a time and then PLS calibrates the remaining standard
descriptor. By using this calibration, the pIC50 of the sample left out
was predicted. This process was repeated until each standard had
been left out once. One other reasonable choice for the optimum
number of factors would be that number that yields the minimum
RMSEC. As there are a finite number of samples in the training
set, in many cases, the minimum RMSEC value causes underfitting
or overfitting for unknown samples that were not included in the
model. A solution to this problem has been suggested by Haaland
et al. and Goodarzi et al. (42,43) in which the RMSEC values for all
previous factors are compared to the RMSEC value at the minimum.
The F-Statistical test can be used to determine the significance of
RMSEC values greater than the minimum. In all instances, the num-
ber of factors for the first RMSEC values whose F-ratio probability
drops below 0.75 was selected as the optimum. We tested two
ways for finding the best Lv to make a model where both of them
present that four is the best number of component. Figure 2A
shows the root mean square errors of calibration (RMSEC) and vali-
dation (RMSECV) as a function of number of components, while Fig-
ure 2B shows the Q2 ⁄ R2 cross-validation as a function of the
number of components. It is clear from Figure 2A that the minimum
number of components is four which is the same maximum number
of components in Figure 2B. The following equation represents the
best model achieved by GA-PLS:
pIC50 ¼ 3:405737ð1:447Þ þ 0:525607ð0:052ÞTE2
þ 0:911090ð0:236ÞUiþ 2:586873ð0:369ÞGATS5e
 47:069316ð8:558ÞMor13e 0:207581ð0:027ÞATS7m
þ 13:338116ð3:599ÞSs 0:001142ð0:000ÞMor27e
þ 49:494231ð7:841ÞRDF035e ð15Þ
The best model shown above reveals that the most significant con-
tribution comes from the RDF035e.
Results of GA-SVM
The quality of SVM for regression depends on several parameters
namely, kernel type k, which determines the sample distribution
in the mapping space, and its corresponding parameter r, capac-
ity parameter C, and e-insensitive loss function. The three param-
eters were optimized in a systematic grid search-way and the
final optimal model was determined (see Table 3). Optimization of
SVM parameters was performed by systematically changing their
values in the training step and calculating the RMSE of the
model using 5-fold cross-validation. The optimal value for e
depends on the type of noise present in the data, which is usu-
ally unknown. Even if enough knowledge of the noise is available
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Figure 2: A) Root mean square
errors of calibration (RMSEC) and
validation (RMSECV) as a function
of number of components. B) Cros-
s-validation (Q2 ⁄ R2 as a function of
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Table 3: Results and statistical parameters of GA-PLS and GA-
SVM
Parameters GA-SVM GA-PLS
NOCa 4
Q2 LOOb 0.9672 0.8259
r 0.5
e 0.06
C 8
RMSEP Training set 0.2027 0.3934
Test set 0.2751 0.3962
RSEP(%) Training set 3.1520 6.1156
Test set 4.0216 5.7928
MAE(%) Training set 6.5080 8.9351
Test set 18.093 21.745
R2 Training set 0.9800 0.8935
Test set 0.9355 0.8603
F statistical Training set 1815.2 310.26
Test set 72.481 30.792
t test Training set 42.606 17.614
Test set 8.5136 5.5491
RMSEP, root mean square error of prediction, RSEP, relative standard error
of prediction, MAE, mean absolute error.
aNumber of components.
bQ2 Leave-one-out cross-validation.
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Figure 3: Variation of RMSE versus epsilon values.
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to select an optimal value for e, there will be some practical con-
sideration of the number of resulting support vectors. e-insensitiv-
ity prevents the entire training set from meeting boundary
conditions and allows the possibility of sparsity in the dual formu-
lations solution. Therefore, choosing the appropriate value of e is
a critical step. To find an optimal value for e, the RMSE of SVM
models with different e values was calculated. The variation of
RMSE versus epsilon values is plotted in Figure 3. As shown in
this figure, the optimal value of e was 0.06. The other parameter
is the regularization parameter C that controls the trade-off
between maximizing the margin and minimizing the training error.
If C value is too small, then insufficient stress will be placed on
fitting the training data. On the other hand, if C value is too
large, then the SVM model will overfit the training data. To find
an optimal value of C, the RMSE of SVM models with different
C values was calculated. Moreover, to inspect any interactions
between C and epsilon, after optimization of the C value, the
epsilon value varied. The results indicate that the value of opti-
mized epsilon did not vary at this stage which illustrates their
independency.
Six general statistical parameters were selected to evaluate the
prediction ability of the constructed model. These parameters are:
root mean square error of prediction (RMSEP), relative standard
error of prediction (RSEP), mean absolute error (MAE), square of
correlation coefficient (R2), F-statistical and t test. Table 3 shows
the results of GA-PLS and GA-SVM and the calculated statistical
parameters. This table shows that the results of the GA-SVM are
better than GA-PLS. Figure 4A shows calculated pIC50 against
experimental values, while Figure 4B shows their residual values
against the experimental pIC50 using GA-SVM. Figure 5A shows
the calculated pIC50 against the experimental values, while Fig-
ure 5B shows their residual values against the experimental pIC50
using GA-PLS. Figure 1 and Table 1 shows that the inhibitors con-
sist of some different classes with very diverse substituents which
could help explain the models and the selected descriptors obtained
to predict the inhibitory activity of non-peptide HIV-1 protease inhib-
itors. For example, selection of topographic electronic descriptor
(TE2) reflects to some extent, differences in size, shape, and consti-
tution. Such quantities affect the electronic charge distribution and
interatomic distance of the molecules. The empirical descriptor (Ui)
represents limited subsets of compounds and cannot be extended
to classes of compounds different from those for which they were
defined (compounds 1–5 in Table 1). These empirical descriptors are
related to specific or local structural factors present in the mole-
cules. The other selected descriptors are related to the geometry of
molecules such as 3D atomic coordinates, atomic property, and dis-
tance distribution in the geometrical representation of a molecule.
In addition, these non-peptide HIV-1 protease inhibitors have shown
their ability to participate in complex biological phenomena. It is
worth mentioning to the best of our knowledge that no QSAR
model was found for this class up to now. Therefore, the develop-
ment of a robust and interpretable QSAR model that is able to
accurately predict the pIC50 is necessary and this article is the first
to report such a model.
Conclusion
PLS and SVM were used to develop QSAR models for the predic-
tion of the inhibitory activity of non-peptide HIV-1 protease inhibi-
tors. The built models clearly demonstrate good correlations
between the structure and inhibitory activity of the studied com-
pounds. Eight descriptors were selected with genetic algorithm. The
9
Training set
Test set
Training set
Test set
8.5
0.7
0.5
0.3
0.1
–0.1Re
sid
ua
ls
–0.3
–0.5
–0.7
8
7.5
7
6.5
5
6
5.5
4.5
4
3.5
3
98.587.576.55 65.54.543.53 98.587.576.55 65.5
Experimental pIC50Experimental pIC50
Pr
ed
ic
te
d 
pI
C 5
0
4.543.53
A B
Figure 4: A) Calculated pIC50
against the experimental values u-
sing GA-SVM. B) Residual values
against experimental pIC50 using
GA-SVM.
9
Training set
Test set
Training set
Test set
8.5
1.5
1
0.5
0
–0.5
R
es
id
ua
ls
–1
–1.5
8
7.5
7
6.5
5
6
5.5
4.5
4
3.5
3
98.587.576.55 65.54.543.53 98.587.576.55 65.5Experimental pIC50Experimental pIC50
Pr
ed
ic
te
d 
pI
C 5
0
4.543.53
A B
Figure 5: A) Calculated pIC50
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selected descriptors, which are TE2, Ui, GATS5e, Mor13e, ATS7m,
Ss, Mor27e, and RDF035e were found to be important factors con-
trolling the inhibitory activity. Comparison between PLS and SVM
methods demonstrates that the performance of SVM model is bet-
ter than that of PLS, which indicates that the non-linear model is
able to describe the relationship between the structural descriptors
and the inhibitory activity more accurately. The proposed models
will help identifying new HIV-1 protease inhibitors and provide
insight to guide their development.
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